A practice-level look at how gastroenterology clinicians individualize IBS care, combine pharmacologic, dietary and gut-brain strategies, and respond when symptom control remains incomplete.
Audience: Gastroenterology clinicians
Countries: 5
Completion Rate: 90%
SGID: 8974878
-Hero findings
– Quick Read — Key Findings
Irritable bowel syndrome is a disorder of gut-brain interaction in which bowel pattern, abdominal pain or discomfort, bloating, dietary triggers, comorbidities, treatment response, and day-to-day impact can point in different directions at the same time.
That complexity runs through current guidance. The American College of Gastroenterology guideline supports a positive diagnostic strategy, accurate subtype classification, a limited low-FODMAP trial for appropriate patients, subtype-relevant pharmacologic treatment, and gut-directed psychotherapy, and the American Gastroenterological Association’s IBS quality indicators place diagnosis, subtype-directed treatment, dietary counseling, and brain-gut behavioral therapy inside the same framework. The MDForLives survey asks what that layered model looks like in gastroenterology practice: what clinicians prioritize when personalizing treatment, what they change after an inadequate response, how gut-brain interaction alters management, and why satisfactory control can remain elusive despite the options available.
92.1% consider symptom severity, treatment response, and quality-of-life impact when individualizing IBS treatment; 76.3% also consider IBS subtype and predominant symptoms.
Subtype still matters, because constipation-predominant, diarrhea-predominant, mixed, and other patterns can point to different choices, but the most selected factor is broader: how severe the symptoms are, how the patient has already responded, and how much the condition disrupts daily life. That is practical, since two patients with the same stool-pattern subtype may need different next steps if one has persistent pain, repeated treatment failure, major functional impairment, or overlapping symptoms. Personalization starts with phenotype but does not end there.
86.8% report using symptom-directed or subtype-specific pharmacologic treatment, 73.7% dietary interventions and self-management, and 55.3% neuromodulators or gut-directed psychological or behavioral therapies.
The mix fits a pathway where medication, diet, self-management, and gut-brain treatment can all be relevant; the gap is not whether these tools exist but how deliberately they are sequenced and combined. The AGA’s clinical practice update on diet in IBS emphasizes structured dietary intervention and dietitian support where appropriate, and the survey suggests these non-pharmacologic approaches are already a substantial part of real-world care, even if specialized multidisciplinary management is used less often.
81.6% say they optimize treatment or switch to a different mechanism after an inadequate initial response; 55.3% reassess the diagnosis, phenotype, adherence, or overlapping conditions.
The pattern is not simply escalation: reassessment and augmentation sit alongside switching, so clinicians are asking whether the original phenotype, diagnosis, or target still fits before moving on. Referral is chosen far less often than treatment optimization, which likely reflects both the specialist audience and the fact that many difficult IBS decisions are still handled within routine gastroenterology. The larger point is that an inadequate response becomes a decision about mechanism, phenotype, and combination care.
When gut-brain interaction appears important, 37.8% prioritize gut-directed psychological or behavioral therapy and another 37.8% consider a neuromodulator or combined pharmacologic treatment.
Gut-directed psychological or behavioral therapy
Neuromodulator or combined pharmacologic treatment
Education and symptom-management strategies
Address mainly after conventional treatment fails
The tie between behavioral and pharmacologic gut-brain strategies is revealing: the gut-brain axis is not read as one specific intervention, but as a reason to broaden the treatment frame. Only 5.4% mainly address it after conventional treatment fails, which aligns with current quality recommendations that treat brain-gut behavioral therapies as part of IBS management, not a last-resort add-on.
56.8% estimate that only 25–49% of their IBS patients achieve satisfactory symptom control with the first treatment strategy, while 70.3% identify persistent symptoms or limited response to available therapies as a major obstacle to sustained control.
That first-treatment estimate helps explain why IBS management feels iterative: the largest group does not expect a majority to reach satisfactory control on the first strategy, so treatment has to be designed with a next step in mind rather than assuming the initial choice settles the pathway. The sustainability data reinforces it, persistent symptoms or limited response leads, followed by patient heterogeneity and overlapping symptoms at 59.5%, with adherence, intolerance, dietary complexity, and gut-brain factors adding further friction.
Across the survey, gastroenterology clinicians describe a pathway already broader than medication alone: severity, quality-of-life impact, subtype, diet, comorbidities, gut-brain factors, prior response, and access all compete for attention, and while pharmacologic therapy remains central, dietary intervention, self-management, neuromodulation, and behavioral care are already part of the practical mix.
The difficulty appears when that mix meets a patient whose symptoms persist. Clinicians most often optimize or switch treatment, but many also reassess phenotype and add non-pharmacologic or combination strategies; the first strategy is rarely assumed to be enough for most patients, and persistent symptoms remain the most selected reason sustained control is hard.
Future priorities point the same way: better approaches for refractory IBS and multimodal care lead the three-to-five-year outlook, followed by more targeted phenotype-based treatment and stronger integration of gut-brain and personalized dietary care, with open responses calling for clearer phenotype targeting, microbiome-directed options, better follow-up, and more durable relief.
You have read the summary
Direct answers to common clinical questions about personalized treatment, gut-brain care, refractory symptoms, diet, and what happens after an inadequate response.
Direct answers to the questions healthcare professionals are most likely to ask about these findings.
